Home management of haemophilia

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia 2004-03, Vol.10 (2), p.118-133
• Main Authors: Teitel, J. M., Barnard, D., Israels, S., Lillicrap, D., Poon, M.-C., Sek, J.
• Format: Article
• Language: English
• Subjects: Blood Coagulation Factors - therapeutic use; Clinical Protocols; Comprehensive Health Care; Family Health; Forecasting; haemophilia; Hemophilia A - prevention & control; Hemophilia A - therapy; Hemophilia B - prevention & control; Hemophilia B - therapy; history; Home Care Services - organization & administration; home management; Humans; inhibitors; North America; prophylaxis; Quality of Life; review
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1046/j.1365-2516.2003.00853.x

The demonstrated benefits of home care for haemophilia include improved quality of life, less pain and disability, fewer hospitalizations, and less time lost from work or school. Although reduced mortality has not been demonstrated, the substantial increase in longevity since the early 1980s correlates with the introduction of home treatment and prophylaxis programmes. These programmes must be designed and monitored by haemophilia treatment centres (HTC), which are staffed with professionals with broad and complementary expertise in the disease and its complications. In return, patients and their families must be willing to accept the reciprocal responsibilities that come from administering blood products or their recombinant equivalents at home. Patients with inhibitors to factors VIII or IX pose special challenges, but these complications do not obviate participation in home care programmes. Home care was an essential prerequisite to the introduction of effective prophylactic factor replacement therapy. Prophylaxis offers significant improvements in quality of life, but requires a substantial commitment. The use of implantable venous access devices can eliminate some of the difficulty and discomfort of peripheral venous access in small children, but brings additional risks. The future holds the promise of factor concentrates for home use that have longer half‐lives, or can be administered by alternate routes. Knowledge of patient genotypes may allow treatments tailored to avoid complications such as inhibitor development. Gene therapy trials, which are currently ongoing, will ultimately lead to gene‐based treatments as a complement to traditional protein‐based therapy.